Related Experiment Videos
Effects of somatostatin on insulin and glucagon in patients with insulinoma
Abstract:
Effects of somatostatin on fasting and arginine-or tolbutamide-stimulated insulin release were studied in four patients with insulinoma. Somatostatin (bolus or bolus + infusion) reduced fasting insulin values in all patients; insulin response to tolbutamide was partially reduced in two patients; somatostatin bolus impaired the insulin response to arginine. Fasting glucagon levels and glucagon response to arginine were also reduced by somatostatin. These results indicate the potential usefulness of somatostatin in the diagnosis of insulinoma even if its effect on insulin is only partial.
Insights
Somatostatin effectively lowered fasting insulin and glucagon levels in patients with insulinoma. While it partially reduced insulin response to tolbutamide, it impaired arginine-stimulated insulin release, suggesting diagnostic potential for insulinoma.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Oncology
Background:
- Insulinoma is a rare tumor causing hypoglycemia due to excessive insulin secretion.
- Accurate diagnosis of insulinoma is crucial for effective management.
- Somatostatin is a hormone with inhibitory effects on insulin and glucagon release.
Purpose of the Study:
- To investigate the effects of somatostatin on insulin and glucagon secretion in patients with insulinoma.
- To evaluate the potential diagnostic utility of somatostatin in insulinoma.
Main Methods:
- Four patients with diagnosed insulinoma participated in the study.
- Somatostatin was administered via bolus or bolus plus infusion.
- Fasting insulin and glucagon levels were measured.
- Insulin and glucagon responses to arginine and tolbutamide stimulation were assessed with and without somatostatin.
Main Results:
- Somatostatin reduced fasting insulin levels in all patients.
- Fasting glucagon levels and glucagon response to arginine were decreased by somatostatin.
- The insulin response to tolbutamide was partially reduced in two patients.
- Somatostatin administration impaired the insulin response to arginine.
Conclusions:
- Somatostatin demonstrates a significant impact on insulin and glucagon secretion in insulinoma patients.
- Despite partial effects on insulin response, somatostatin shows potential as a diagnostic tool for insulinoma.
- Further research may refine the use of somatostatin in diagnosing rare endocrine tumors.